SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    A. Curran, P. Monteiro, P. Domingo, J. Villar, A. Imaz, E. Martinez, I. Fernandez, H. Knobel, D. Podzamczer, J. A. Iribarren, M. Penaranda, M. Crespo, A. Curran, E. Ribera, J. Navarro, M. Crespo, P. Monteiro, E. Martinez, I. Fernandez, P. Domingo, J. Villar, H. Knobel, A. Imaz, D. Podzamczer, M. Ibarguren, J. A. Iribarren, M. Penaranda, M. Riera, Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group, Journal of Antimicrobial Chemotherapy, 2014, 69, 5, 1390

    CrossRef

  2. 2
    K. A. Sutherland, J. Ghosn, J. Gregson, J. L. Mbisa, M. L. Chaix, I. Cohen Codar, J. F. Delfraissy, C. Delaugerre, R. K. Gupta, HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir, Journal of Antimicrobial Chemotherapy, 2014,

    CrossRef

  3. 3
    K. A. Sutherland, J. L. Mbisa, J. Ghosn, M.-L. Chaix, I. Cohen-Codar, S. Hue, J.-F. Delfraissy, C. Delaugerre, R. K. Gupta, Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length gag-protease genes, Journal of Antimicrobial Chemotherapy, 2014,

    CrossRef

  4. 4
    María Inés Figueroa, Omar Sued, Pedro Cahn, What to do Next? Second-line Antiretroviral Therapy, Current Treatment Options in Infectious Diseases, 2014, 6, 2, 159

    CrossRef

  5. 5
    R. Tubiana, L. Mandelbrot, J. Le Chenadec, S. Delmas, C. Rouzioux, D. Hirt, J.-M. Treluyer, D. Ekoukou, E. Bui, M.-L. Chaix, S. Blanche, J. Warszawski, J. Ngondi, N. Chernai, J. Teglas, C. Laurent, P. Huyn, J. Le Chenadec, S. Delmas, J. Warszawski, P. Muret, Y. Baazia, V. Jeantils, E. Lachassine, A. Rodrigues, A. Sackho, I. Sagnet-Pham, S. Tassi, D. Breilh, X. Iriard, G. Andre, D. Douard, S. Reigadas, D. Roux, I. Louis, P. Morlat, S. Pedebosq, J. Barre, E. Estrangin, E. Fauveau, V. Garrait, P. Ledudal, C. Pichon, L. Richier, A. Thebault, C. Touboul, D. Bornarel, V. Chambrin, L. Clech, P. Dubreuil, L. Foix L'helias, O. Picone, H. Schoen, M. Stralka, C. Crenn-Hebert, C. Floch-Tudal, E. Hery, H. Ichou, L. Mandelbrot, F. Meier, V. Tournier, S. Walter, P. Chevojon, A. Devidas, M. Granier, M. Khanfar-boudjemai, C. Malbrunot, R. Nguyen, B. Ollivier, E. Radideau, I. Turpault, T. Jault, A. Barrail, C. Colmant, C. Fourcade, C. Goujard, C. Pallier, D. Peretti, A. Taburet, L. Bocket, S. D'angelo, F. Godart, Y. Hammou, N. Houdret, F. Mazingue, B. Thielemans, C. Brochier, L. Cotte, F. Januel, T. Le Thi, M. Gagneux, A. Bozio, J. Massardier, K. Kebaili, A. K. Ben, B. Heller-Roussin, C. Riehl, S. Roos, F. Taccot, C. Winter, J. Arias, C. Brunet-Francois, E. Dailly, L. Flet, V. Gournay, F. Mechinaud, V. Reliquet, N. Winner, G. Peytavin, C. Bardin, N. Boudjoudi, A. Compagnucci, C. Guerin, A. Krivine, E. Pannier, D. Salmon, J. Treluyer, G. Firtion, D. Ayral, N. Ciraru-Vigneron, M. Mazeron, N. Rizzo Badoin, H. Trout, A. Benachi, C. Boissand, D. Bonnet, S. Boucly, S. Blanche, M. Chaix, C. Duvivier, S. Parat, V. Cayol, S. Oucherif, C. Rouzioux, J. Viard, M. Bonmarchand, I. De Montgolfier, M. Dommergues, M. Fievet, M. Iguertsira, M. Pauchard, F. Quetin, C. Soulie, R. Tubiana, A. Faye, S. Magnier, E. Bui, B. Carbonne, A. Daguenel Nguyen, N. Harchi, M. Meyohas, J. Poirier, J. Rodriguez, F. Herve, G. Pialloux, A. Dehee, C. Dollfus, I. Tillous Borde, G. Vaudre, A. Wallet, M. Allemon, P. Bolot, A. Boussairi, C. Chaplain, D. Ekoukou, N. Ghibaudo, J. Kana, M. Khuong, M. Weil, N. Entz-Werle, P. Livolsi Lutz, L. Beretz, M. Cheneau, M. Partisani, M. Schmitt, P. Acar, E. Armand, A. Berrebi, C. Guibaud Plo, M. Lavit, F. Nicot, J. Tricoire, F. Ajana, T. Huleux, Lopinavir/Ritonavir Monotherapy as a Nucleoside Analogue-Sparing Strategy to Prevent HIV-1 Mother-to-Child Transmission: The ANRS 135 PRIMEVA Phase 2/3 Randomized Trial, Clinical Infectious Diseases, 2013, 57, 6, 891

    CrossRef

  6. 6
    Kit N. Simpson, Pamela P. Pei, Jörgen Möller, Robert W. Baran, Birgitta Dietz, William Woodward, Kristen Migliaccio-Walle, J. Jaime Caro, Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States, PharmacoEconomics, 2013, 31, 5, 427

    CrossRef

  7. 7
    Guillemette Antoni, Julien Guergnon, Céline Meaudre, Assia Samri, Faroudy Boufassa, Cécile Goujard, Olivier Lambotte, Brigitte Autran, Christine Rouzioux, Dominique Costagliola, Laurence Meyer, Ioannis Theodorou, MHC-driven HIV-1 control on the long run is not systematically determined at early times post-HIV-1 infection, AIDS, 2013, 27, 11, 1707

    CrossRef

  8. 8
    Curtis Cooper, Charles la Porte, Harout Tossonian, John Sampalis, Nabil Ackad, Brian Conway, A Pilot, Prospective, Open-Label Simplification Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Once-Daily Lopinavir-Ritonavir Monotherapy in HIV-HCV Coinfected Patients: The MONOCO Study, HIV Clinical Trials, 2012, 13, 4, 179

    CrossRef

  9. 9
    John A. Bartlett, Heather J. Ribaudo, Carole L. Wallis, Evgenia Aga, David A. Katzenstein, Wendy S. Stevens, Michael R. Norton, Karin L. Klingman, Mina C. Hosseinipour, John A. Crump, Khuanchai Supparatpinyo, Sharlaa Badal-Faesen, Beatrice A. Kallungal, Nagalingeswaran Kumarasamy, Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings, AIDS, 2012, 26, 11, 1345

    CrossRef

  10. 10
    Elena Reina, Ramón San Miguel, Natalia Larrea, Patricia Garcia, Victor Napal, Potential for simplification of HIV treatment with boosted protease inhibitor monotherapy, International Journal of Clinical Pharmacy, 2012, 34, 6, 911

    CrossRef

  11. 11
    Miriam Estébanez, Jose R. Arribas, Protease Inhibitor Monotherapy: What Is Its Role?, Current HIV/AIDS Reports, 2012, 9, 2, 179

    CrossRef

  12. 12
    Andrea De Maria, Andrea Cossarizza, CD4saurus Rex &HIVelociraptor vs. development of clinically useful immunological markers: a Jurassic tale of frozen evolution, Journal of Translational Medicine, 2011, 9, 1, 93

    CrossRef

  13. 13
    Cecilia Pizzocolo, Antonella Castagna, Adriano Lazzarin, HIV protease inhibitors: present and future, Future Virology, 2011, 6, 5, 571

    CrossRef

  14. 14
    A Sarah Walker, Diana M Gibb, Monitoring of highly active antiretroviral therapy in HIV infection, Current Opinion in Infectious Diseases, 2011, 24, 1, 27

    CrossRef

  15. 15
    V. Avettand-Fenoel, P. Flandre, M. L. Chaix, J. Ghosn, C. Delaugerre, F. Raffi, P. NgoVan, I. Cohen-Codar, J. F. Delfraissy, C. Rouzioux, Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial, Journal of Antimicrobial Chemotherapy, 2010, 65, 5, 1005

    CrossRef

  16. 16
    Jamie D. Croxtall, Caroline M. Perry, Lopinavir/Ritonavir, Drugs, 2010, 70, 14, 1885

    CrossRef

  17. 17
    S. Naggie, C. Hicks, Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options, Journal of Antimicrobial Chemotherapy, 2010, 65, 6, 1094

    CrossRef